Redmile Group, LLC
Redmile Group, LLC reported 44 holdings worth US$1.37B as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Redmile Group, LLC reported 44 holdings worth US$1.37B as of Sep 30, 2026. Largest: Nurix Therapeutics, Inc., Krystal Biotech, Inc. and Scholar Rock Holding Corporation. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 44
- Value as reported
- US$1.37B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Nurix Therapeutics, Inc. | 7.9M | US$187M | 13.7% |
| Krystal Biotech, Inc. | 528K | US$175M | 12.8% |
| Scholar Rock Holding Corporation | 3.03M | US$147M | 10.7% |
| Stoke Therapeutics, Inc. | 3.87M | US$101M | 7.4% |
| Immunome, Inc. | 4.36M | US$93.8M | 6.9% |
| Absci Corporation | 6.67M | US$71.9M | 5.3% |
| Electra Therapeutics, Inc. | 5.43M | US$61.1M | 4.5% |
| Annexon, Inc. | 14.3M | US$60.4M | 4.4% |
| Neurogene Inc. | 1.56M | US$43.5M | 3.2% |
| Regenxbio Inc. | 5.05M | US$38M | 2.8% |
| Shattuck Labs, Inc. | 5.09M | US$34.7M | 2.5% |
| Fate Therapeutics, Inc. | 12.9M | US$30.5M | 2.2% |
| Silence Therapeutics PLC | 2.46M | US$26.9M | 2.0% |
| Beam Therapeutics Inc. | 1.06M | US$26M | 1.9% |
| Attovia Therapeutics, Inc. | 1.16M | US$19.9M | 1.5% |
| AgomAb Therapeutics NV | 1.74M | US$19.3M | 1.4% |
| Nuvation Bio Inc. | 3.03M | US$17M | 1.2% |
| ADARx Pharmaceuticals, Inc. | 769K | US$15.3M | 1.1% |
| IDEAYA Biosciences, Inc. | 381K | US$14.7M | 1.1% |
| Solid Biosciences Inc. | 1.94M | US$14.1M | 1.0% |
| Zymeworks Inc. | 492K | US$13M | 0.95% |
| Obsidian Therapeutics, Inc. | 833K | US$11.4M | 0.84% |
| BioMarin Pharmaceutical Inc. | 190K | US$11.4M | 0.83% |
| Climb Bio, Inc. | 974K | US$11.2M | 0.82% |
| Celldex Therapeutics, Inc. | 322K | US$10.4M | 0.76% |
| ALX Oncology Holdings Inc. | 7.19M | US$9.99M | 0.73% |
| Aura Biosciences, Inc. | 1.55M | US$9.75M | 0.71% |
| Cogent Biosciences, Inc. | 297K | US$9.5M | 0.70% |
| CeriBell, Inc. | 387K | US$9.43M | 0.69% |
| Odyssey Therapeutics, Inc. | 375K | US$8.32M | 0.61% |
| Xenon Pharmaceuticals Inc. | 191K | US$7.1M | 0.52% |
| Cyberonics Inc | 84,132 | US$6.44M | 0.47% |
| Atara Biotherapeutics, Inc. | 637K | US$5.41M | 0.40% |
| Insmed Incorporated | 42,902 | US$4.9M | 0.36% |
| Eupraxia Pharmaceuticals, Inc. | 520K | US$4.73M | 0.35% |
| DBV Technologies SA | 373K | US$4.39M | 0.32% |
| ORIC Pharmaceuticals, Inc. | 293K | US$3.94M | 0.29% |
| TCGX Acquisition Corp. | 300K | US$3.75M | 0.27% |
| Prime Medicine, Inc. | 1.15M | US$3.5M | 0.26% |
| Invivyd, Inc. | 2.29M | US$1.99M | 0.15% |
| Ocular Therapeutix, Inc. | 244K | US$1.87M | 0.14% |
| Ardelyx, Inc. | 524K | US$1.79M | 0.13% |
| Pliant Therapeutics, Inc. | 772K | US$834K | 0.06% |
| Establishment Labs Holdings Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC
Related